Chemoreflex Sensitivity in HFpEF
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- Diagnostic Test: chemoreflex evaluation
- Registration Number
- NCT06309537
- Lead Sponsor
- Istituto Auxologico Italiano
- Brief Summary
Patients with heart failure and a preserved left ventricular ejection fraction (HFpEF) almost invariably complain of exertional breathlessness. Abnormal cardiac hemodynamics with pulmonary congestion are believed to trigger dyspnea in this patients. However, some patients may complain of exertional breathlessness which seems to be out of proportion as compared with hemodynamic abnormalities.
Chemoreflex sensitivity accounts for the ventilatory responses to a variety of chemical stimuli, including carbon dioxide produced by the organism during exercise. Chemoreflex sensitivity can be augmented in heart failure with reduced left ventricular ejection fraction, and an increased chemoreflex sensitivity has been linked to symptoms, neurohumoral activation, breathing disturbances, and adverse prognosis.
However, the clinical correlates and implications of chemoreflex sensitivity in HFpEF have not been accurately studied.
We aim to characterize chemoreflex sensitivity in patients with a diagnosis of HFpEF, and to correlate chemoreflex sensitivity with clinical and hemodynamic characteristics.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 60
- diagnosis of symptomatic HFpEF (group 1)
- diagnosis of asymptomatic left ventricular diastolic dysfunction with echocardiographic signs of PH (group 2)
- healthy volunteers (group 3)
- breastfeeding or childbearing
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description HFpEF chemoreflex evaluation symptomatic patients with heart failure with preserved ejection fraction healthy volonteers chemoreflex evaluation - asymptomatic PH-LHD chemoreflex evaluation asymptomatic left ventricular diastolic dysfunction with echocardiographic signs of pulmonary hypertension
- Primary Outcome Measures
Name Time Method difference in chemoreflex sensitivity between HFpEF and healthy controls 5 years
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Ospedale San Luca IRCCS Istituto Auxologico Italiano
🇮🇹Milan, Italy